Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Report Date: December 24, 2025
Principal Office: Seattle, WA
This filing reports a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) approved YARTEMLEA (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The filing also notes a revision to the original press release to update the conference call date and provide supplemental expert information.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
- Regulatory Approval: FDA approval granted for YARTEMLEA to treat TA-TMA, a fatal complication of stem-cell transplantation.
- Document Revision: The press release attached as Exhibit 99.1 was revised solely to reflect a new conference call date and additional expert details; no other changes were made to the announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release signed by Gregory A. Demopulos, M.D., President, CEO, and Chairman, highlighting the approval of a therapy targeting the lectin pathway of complement activation.
Outlook and Risks: The filing does not provide specific financial guidance, future revenue projections, or a detailed discussion of risks and contingencies beyond the context of the drug approval.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for YARTEMLEA following FDA approval.
- Review the revised press release (Exhibit 99.1) for the updated conference call details and expert commentary.
- Assess the potential market size for TA-TMA treatments and competitive landscape.
- Monitor upcoming quarterly reports for the financial impact of the new product launch.